Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 Gross Margin % is 75.82% as of Dec. 2025, which is 4% below its 10-year median of 78.73. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 940 Drug Manufacturers companies, CF PharmTech ranks better than 88.51% on this metric.
The historical rank and industry rank for CF PharmTech's Gross Margin % or its related term are showing as below:
HKSE:02652'
s Gross Margin % Range Over the Past 10 Years
Min: 75.82 Med: 78.73 Max: 82.22
Current: 75.82
During the past 4 years, the highestGross Margin % of CF PharmTech was 82.22%. The lowest was 75.82%. And the median was 78.73%.
HKSE:02652's Gross Margin % is ranked better than 88.51% of 940
companies
in the Drug Manufacturers industry
Industry Median: 48.35
vs HKSE:02652: 75.82
CF PharmTech had a gross margin of 75.82% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for CF PharmTech was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
CF PharmTech had a gross margin of 75.82% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
CF PharmTech Gross Margin % Related Terms
CF PharmTech Gross Margin % Historical Data
* Premium members only.
The historical data trend for CF PharmTech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech Gross Margin % Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Gross Margin %
76.61
82.22
80.85
75.82
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Gross Margin %
76.61
82.22
80.85
75.82
HKSE:02652 vs ZTS: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where CF PharmTech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
CF PharmTech (HKSE:02652) has a Gross Margin % of 75.82% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on CF PharmTech and its competitors. This is near median its historical median of 78.73. Over the past decade, CF PharmTech's Gross Margin % has ranged from 75.82 to 82.22. According to the industry distribution chart, CF PharmTech ranks #108 out of 940 companies in the Drug Manufacturers industry, placing it in the top 11.5%.
Is CF PharmTech's Gross Margin % too high?
CF PharmTech's current Gross Margin % of 75.82% is near median its 10-year median of 78.73. Over the past 10 years, this metric has ranged from a low of 75.82 to a high of 82.22. The Drug Manufacturers industry median Gross Margin % is 48.35. CF PharmTech's value of 75.82% is 56.8% above this industry median. Based on the distribution chart, CF PharmTech ranks #108 out of 940 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Gross Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #108 out of 940 companies for Gross Margin %. This places CF PharmTech in the top 12% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.35. CF PharmTech's value of 75.82% is 56.8% above this benchmark. Historically, CF PharmTech's own Gross Margin % has ranged from 75.82 to 82.22 over the past decade. While the company's 10-year median is 78.73 vs. the industry median of 48.35, CF PharmTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.35, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current Gross Margin % of 75.82% is 56.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current Gross Margin % is 75.82%, which is near median its own 10-year median of 78.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Gross Margin % of 75.82%. The current Gross Margin % is 75.82%, which is near median its 10-year median of 78.73 and 56.8% above the Drug Manufacturers industry median of 48.35. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Gross Margin % is 75.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
